VSTM
Verastem, Inc.
$5.73
+0.16 (+2.87%)
At close · Jul 15
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with the applicable accounting standards, these conditions raise substantial doubt about the Company's ability to continue as a going concern for twelve months after the date the condensed consolidated financial statements are issued.”View the 10-Q filed May 7, 2026
Market Cap
$507.03M
Shares
87,873,639
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.73
Open$5.56
Day$5.30–5.76
52W$3.43–11.25
Avg vol 30d3.0M
Short int24.1M · 27.5% float · 7.0d
Short vol55%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 20, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
+29%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
29%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+43%
trailing
6-month return
−10%
trailing
YTD return
−26%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
6 of 156 funds reported for Jun 30 · net +22.3K sh shares · +3 new
Insider flow
Distributing
Net -$4.7K over 90 days · 100% sells
Short interest
Rising
27.47% of float · ▲ +10.9% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+209%
Y/Y
EPS growth
+17%
Y/Y
Free cash flow
$-137.5M
Balance sheet
$164.3M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
+29%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
29%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
6 of 156 funds reported for Jun 30 · net +22.3K sh shares · +3 new
Insider flow
Distributing
Net -$4.7K over 90 days · 100% sells
Short interest
Rising
27.47% of float · ▲ +10.9% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $6 · 29%
52-wk high $11
vs 200-day avg -13%
vs 50-day avg +29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| percentage of commercially eligible patients using Verastem Cares Co-Pay Program | 65% | Q1 call | — |
| unique prescribers to date | 400 | through April call | — |
| AVMAPKI FAKZYNJA CO-PACK net product revenues | $30.9M | full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VSTM
this stock
Verastem, Inc.
|
$507.03M | -25.8% | +285.2% | — | 27.5% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +2.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VSTM | +12.8% | +43.3% | -9.9% | +50.0% | -25.8% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +11.5% | +43.4% | -20.0% | +48.9% | -36.5% |